神经学缓释治疗药物市场

使用旨在调节治疗物质作用的製剂技术，药物开发商正在开发具有缓释特性的製剂。此类製剂技术包括聚乙二醇缀合物（聚乙二醇化）等聚合物，用于封装和包覆新药物。目的是透过控释製剂满足患者依赖性且依从性敏感的药物治疗方案的要求，例如多次给药，透过每日一次或更少的给药即可达到所需的治疗效果。

鑑于慢性病持续需要重复给药，这些适应症代表着巨大的药物量和收入机会，同时挑战该行业开发满足非专业护理人员独特需求的产品。对于设计供患者使用的药物，特定治疗的包装可以提高依从性和治疗结果。在药物传输领域，设计用于容纳预充式註射器和药筒的可重复使用注射装置正在提高使用便利性，并增加替代装置在不断增长的自我注射市场中的份额。

该报告研究了神经病学缓释治疗市场，并讨论了新兴国家的市场开发商、设备设计者和医疗保健行销人员为患者自我管理而设计的注射设备的经济、技术和机会。供应链。

目录

执行摘要

市场机会

• 执行摘要
• 神经科药物市场动态
• 自我管理倾向
• 给药途径
• 药物配方创新
• 神经系统药物和用品包装
• 人体工学
• 神经科药物注射给药
• 初级包装
• 注射装置设计的创新
• 给药装置选择问题
• 治疗需求的驱动因素
• 关键市场因素
• MR神经产物分析
• 独特的复合技术
• ChroniJect(Oakwood Laboratories/Pharma Sophia)
• CriticalMix(Critical Pharmaceutical)
• Depoform (Pasila)
• FluidCrystal（Camalus）
• LinkeRx（Alkermes）
• Medisorb（Alkermes）
• Medusa（Recifarm/Abadel）
• Nano crystal（Alkermes）
• Optisome（Talon/Spectrum）
• polyactive（Octoplus）
• Q-Sphera（Midatec Pharma）
• Saber/Saib（Durect）
• SynBiosys (Innocore)
• TransCon（ascendis）
• 物理製程控制方法
• 超临界流体
• 用于奈米颗粒配方的 SCF
• Formulaplex（超临界溶液）
• Ferro
• 乳液的 SCF 萃取 (SFEE)
• 稳定
• 管理因素
• 治疗药物市场领域
• 精神分裂症
• 躁郁症
• 市场领域分析与预测
• 关键市场因素
• 经济因素
• 技术要素
• 监管因素
• 风险因素
• 预测和市场数据
• 公司简介

Using formulation technologies designed to modulate the effect of therapeutic substances, drug developers are creating formulations that exhibit extended release profiles. These chemistries include polymers such as polyethylene glycol-complexed (PEGylated), which are used to product encapsulated and coated versions of new APIs. The goal is to address the requirement for patient-dependent, and therefore compliance-sensitive, drug treatment protocols such as multiple dosing through controlled release formulations that provide the desired therapeutic effect with dosing of once-a-day or less.

The report provides developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, opportunities for injection devices that are designed for patient self-administration. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Evolution in Therapeutic Care

Because of the ongoing need for repeat dosing posed by chronic diseases, these indications represent significant drug volume and revenue opportunities, while simultaneously challenging the industry to develop products that meet the unique needs of the non-professional caregiver. For drugs designed to be administered by the patient, therapy-specific packaging is improving adherence and treatment outcomes. In the area of delivery, reusable injection devices designed to accept prefilled syringes or drug cartridges are improving ease-of-use and increasing the alternative device share of the growing self-injection market.

Features:

• Numerous graphs, charts, tables and visualizations complement the analysis

• Forecasts, projections of future market activity are derived using standard modeling and statistical techniques.

What You Will Learn:

• Analyzes and evaluates modified release neurology therapeutics products and assesses the market potential for existing and probable future products

• Analyzes product strategies, technologies and market development issues

• Provides detailed analysis of neurology market segments, market demographics, and therapeutic strategies

• Profiles market sector companies, their product development activities, business strategies, and corporate alliances and affiliations

• Evaluates the impact of economic, technology, and regulatory factors on neurology drug markets

Table of Contents

Executive Summary

The Market Opportunity

• Executive Summary
• The Neurological Drug Market Dynamics
• The Trend Toward Self-Administration
• Route of Administration
• Innovation in Drug Formulation
• Neurological Drugs and As-supplied Packaging
• Human Engineering/Ergonomics
• Delivering Neurological Drugs via Injection
• Primary Packaging
• Innovation in Injectable Device Designs
• Drug Delivery Device Selection Issues
• Therapeutic Demand Drivers
• Key Market Factors
• MR Neurological Product Analysis
• Proprietary Formulation Technology
• ChroniJect (Oakwood Laboratories/PharmaSophia)
• CriticalMix (Critical Pharmaceuticals)
• Depofoam (Pacira)
• FluidCrystal (Camarus)
• LinkeRx (Alkermes)
• Medisorb (Alkermes)
• Medusa (Recipharm/Avadel)
• Nanocrystals (Alkermes)
• Optisomes (Talon/Spectrum)
• PolyActive (Octoplus)
• Q-Sphera (Midatech Pharma)
• SABER/SAIB (DURECT)
• SynBiosys (Innocore)
• TransCon (Ascendis)
• Physical Process Control Methods
• Supercritical Fluid
• SCF for Nanoparticle Formulations
• Formulplex (Supercritical Solutions)
• Ferro
• SCF extraction of emulsions (SFEE)
• Stability
• Administration Factors
• Therapeutic Market Sectors
• Schizophrenia
• Bipolar Disorder
• Market Sector Analysis and Forecasts
• Key Market Factors
• Economic Factors
• Technology Factors
• Regulatory Factors
• Risk Factors
• Forecasts and Market Data
• Company Profiles